Go Back
Altoida
Altoida is a pioneer in developing digital biomarkers of neurological conditions, including Alzheimer’s Disease, using augmented reality and machine learning.
More Details
Our technology platform is designed to enable an objective evaluation of an individual’s cognitive health and function, which may potentially allow for faster patient selection for clinical trials, as well as sensitive monitoring of disease progression and treatment response. Altoida is a privately-held, venture-backed, commercial stage company and our proprietary evidence-based platform is founded on more than 20 years of scientific research and published in multiple peer-reviewed papers including Nature Digital Medicine.